ARNA Arena Pharmaceuticals, Inc. Stock Quote

ARNA [NASD]

Index	-	P/E	-	EPS (ttm)	-7.05	Insider Own	0.10%	Shs Outstand	57.78M	Perf Week	-0.94%
Market Cap	4.64B	Forward P/E	-	EPS next Y	-7.68	Insider Trans	-82.06%	Shs Float	57.42M	Perf Month	7.59%
Income	-370.90M	PEG	-	EPS next Q	-1.85	Inst Own	98.90%	Short Float	5.95%	Perf Quarter	22.88%
Sales	3.30M	P/S	1405.15	EPS this Y	-192.70%	Inst Trans	7.23%	Short Ratio	6.70	Perf Half Y	17.88%
Book/sh	20.25	P/B	3.97	EPS next Y	-7.70%	ROA	-30.40%	Target Price	95.20	Perf Year	82.20%
Cash/sh	20.24	P/C	3.97	EPS next 5Y	-	ROE	-33.20%	52W Range	32.95 - 90.19	Perf YTD	4.58%
Dividend	-	P/FCF	-	EPS past 5Y	36.80%	ROI	33.20%	52W High	-10.91%	Beta	0.74
Dividend %	-	Quick Ratio	23.20	Sales past 5Y	85.20%	Gross Margin	-	52W Low	143.85%	ATR	3.20
Employees	320	Current Ratio	23.20	Sales Q/Q	-98.50%	Oper. Margin	-	RSI (14)	52.39	Volatility	5.14% 3.93%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	-15.40%	Profit Margin	-	Rel Volume	1.04	Prev Close	79.49
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Feb 23 AMC	Payout	-	Avg Volume	510.24K	Price	80.35
Recom	1.70	SMA20	0.21%	SMA50	3.22%	SMA200	14.05%	Volume	528,992	Change	1.08%

Nov-10-20

Reiterated

Guggenheim

Buy

$115 → $105

Sep-14-20

Resumed

JP Morgan

Overweight

$71

Jun-29-20

Initiated

H.C. Wainwright

Buy

$90

May-18-20

Initiated

Jefferies

Buy

$62

Mar-31-20

Initiated

Guggenheim

Buy

$95

Mar-26-20

Upgrade

BofA/Merrill

Neutral → Buy

$47 → $56

Jan-31-20

Upgrade

JP Morgan

Neutral → Overweight

$58

Nov-13-19

Initiated

BofA/Merrill

Neutral

$51

Dec-13-18

Initiated

Berenberg

Buy

$55

May-31-18

Initiated

RBC Capital Mkts

Outperform

$65

Mar-21-18

Upgrade

Needham

Hold → Buy

$60

Mar-20-18

Reiterated

JMP Securities

Mkt Outperform

$63 → $79

Jan-18-18

Resumed

Credit Suisse

Outperform

$44

Jan-18-18

Initiated

Credit Suisse

Outperform

$44

Jan-03-18

Upgrade

Wells Fargo

Market Perform → Outperform

Jul-11-17

Reiterated

Citigroup

Buy

$23 → $37

Jul-07-17

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

Jun-27-17

Initiated

Citigroup

Buy

$23

May-19-17

Initiated

Leerink Partners

Outperform

Sep-15-16

Initiated

FBR & Co.

Outperform

Feb-24-21 06:54AM	Arena Posts Worse-Than-Feared Quarterly Loss As Sales Disappoint SmarterAnalyst
03:02AM	Arena Pharmaceuticals Inc (ARNA) Q4 2020 Earnings Call Transcript Motley Fool
Feb-23-21 04:41PM	Recap: Arena Pharmaceuticals Q4 Earnings Benzinga
04:05PM	Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter Business Wire
02:30PM	Arena Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:29AM	Arena Pharmaceuticals Earnings Preview Benzinga
Feb-18-21 04:05PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-16-21 04:05PM	Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23 Business Wire
08:30AM	Arena Pharmaceuticals Announces Changes to Board of Directors Business Wire
Feb-11-21 12:15AM	Imagine Holding Arena Pharmaceuticals (NASDAQ:ARNA) Shares While The Price Zoomed 400% Higher Simply Wall St.
Feb-07-21 02:13PM	13 Best Hemp Stocks to Buy Now Insider Monkey
Feb-02-21 09:05AM	Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial Business Wire
Jan-22-21 04:04PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-22-20 04:01PM	Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13 PR Newswire
Dec-18-20 01:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Dec-14-20 07:16PM	Is ARNA A Good Stock To Buy Now? Insider Monkey
Dec-11-20 09:00AM	Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference PR Newswire
Dec-08-20 08:30AM	Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial PR Newswire
Nov-30-20 04:05PM	Arena Pharmaceuticals Announces R&D Leadership Transition Business Wire
Nov-24-20 08:30AM	Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1 PR Newswire
Nov-19-20 05:59PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-13-20 05:25AM	Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Nov-10-20 02:27PM	Here's Why Arena Pharmaceuticals Stock Is Plummeting Today Motley Fool -19.64%
09:40AM	Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data Zacks
05:58AM	Companies Like Arena Pharmaceuticals (NASDAQ:ARNA) Are In A Position To Invest In Growth Simply Wall St.
Nov-09-20 10:00PM	Arena Pharmaceuticals Inc (ARNA) Q3 2020 Earnings Call Transcript Motley Fool
05:07PM	Arena Pharmaceuticals: Q3 Earnings Insights Benzinga
04:05PM	Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis PR Newswire
04:01PM	Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial PR Newswire
02:30PM	Arena Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-20 10:18AM	Earnings Preview for Arena Pharmaceuticals Benzinga
Nov-02-20 08:30AM	Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9 PR Newswire
Oct-28-20 08:30AM	Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company PR Newswire
Oct-27-20 12:30PM	Was The Smart Money Right About Arena Pharmaceuticals, Inc. (ARNA)? Insider Monkey
Oct-20-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Oct-09-20 04:30PM	Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community PR Newswire
Oct-01-20 10:22AM	Analyzing Arena Pharmaceuticals's Unusual Options Activity Benzinga
08:30AM	Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome PR Newswire
Sep-18-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
09:00AM	Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit PR Newswire
Sep-16-20 08:30AM	Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis PR Newswire
Sep-11-20 09:59AM	How Much is Arena Pharmaceuticals' (NASDAQ:ARNA) CEO Getting Paid? Simply Wall St.
Sep-09-20 10:40AM	Hedge Funds Arent Done Buying Arena Pharmaceuticals, Inc. (ARNA) Insider Monkey
Sep-04-20 11:41AM	Stocks To Watch: Arena Pharmaceuticals Sees Relative Strength Rating Rise To 83 Investor's Business Daily
Sep-03-20 04:01PM	Arena Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
Sep-01-20 08:30AM	Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata PR Newswire
Aug-19-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-05-20 04:01PM	Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter PR Newswire
Jul-29-20 04:01PM	Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5 PR Newswire
Jul-17-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-13-20 02:33PM	What Kind Of Shareholders Own Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)? Simply Wall St.
Jul-12-20 12:02PM	Did Hedge Funds Make The Right Call On Arena Pharmaceuticals, Inc. (ARNA) ? Insider Monkey
Jun-18-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-15-20 08:30AM	Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors PR Newswire
Jun-08-20 04:30PM	Arena Pharmaceuticals Announces R&D Leadership Transition PR Newswire
01:28PM	Edited Transcript of ARNA earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-03-20 01:13AM	Hedge Funds Arent Done Buying Arena Pharmaceuticals, Inc. (ARNA) Insider Monkey
Jun-02-20 04:23PM	Why Bristol Myers' Success In Ulcerative Colitis Sent Arena Stock Flying Investor's Business Daily +16.22%
Jun-01-20 04:01PM	Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
09:30AM	Moving Average Crossover Alert: Arena Pharmaceuticals Zacks
May-28-20 08:30AM	Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
May-27-20 04:01PM	Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
May-26-20 08:30AM	Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates PR Newswire
May-22-20 04:30PM	Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders PR Newswire
May-20-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
May-19-20 04:10PM	Galecto Appoints New Chair and Strengthens Board of Directors GlobeNewswire
May-13-20 04:01PM	Arena Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire -6.92%
09:18AM	Is Arena (ARNA) Stock a Solid Choice Right Now? Zacks
May-10-20 08:18AM	Earnings Update: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St.
May-08-20 03:01PM	Arena Pharmaceuticals Inc (ARNA) Q1 2020 Earnings Call Transcript Motley Fool
10:39AM	Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected Zacks
May-07-20 04:01PM	Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results PR Newswire
May-06-20 08:30AM	Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13 PR Newswire
Apr-30-20 08:30AM	Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7 PR Newswire
Apr-24-20 09:00AM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-19-20 08:27AM	If You Had Bought Arena Pharmaceuticals (NASDAQ:ARNA) Shares Three Years Ago You'd Have Made 283% Simply Wall St.
Apr-14-20 01:47PM	ESPAÑOL Empresas de Cannabis con Acciones el NYSE y NASDAQ: Una Lista Completa Benzinga
Apr-10-20 01:09PM	Arena Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference on April 14 PR Newswire
Apr-07-20 08:05PM	Hedge Funds Have Never Been This Bullish On Arena Pharmaceuticals, Inc. (ARNA) Insider Monkey
Apr-01-20 04:01PM	Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR) PR Newswire
Mar-30-20 08:30AM	Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor PR Newswire -5.43%
Mar-18-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire -11.19%
02:29PM	Top Biotech Stocks for Q2 2020 Investopedia
Mar-09-20 01:30PM	6 Cheap Health Care Stocks GuruFocus.com -6.58%
10:18AM	Arena's Pipeline Holds Promise, Plunging Revenues a Concern Zacks
Feb-28-20 05:38AM	Arena Pharmaceuticals, Inc. Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Feb-27-20 01:48PM	Edited Transcript of ARNA earnings conference call or presentation 26-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -5.75%
10:40AM	Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top Zacks
Feb-26-20 04:01PM	Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results PR Newswire
09:36AM	The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates Benzinga
Feb-21-20 04:11PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-20-20 08:30AM	Arena Pharmaceuticals to Present at the Upcoming Investor Conferences PR Newswire
Feb-19-20 04:06PM	Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2019 Financial Results and Provide Corporate Update on February 26 PR Newswire
Feb-13-20 06:09AM	Our Take On Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) CEO Salary Simply Wall St.
Feb-11-20 03:06PM	Arena Pharmaceuticals' Presence at the European Crohn's and Colitis Organisation (ECCO) Congress Further Highlights Commitment to the GI Community PR Newswire
Jan-31-20 03:45PM	Top Marijuana Stocks on the NASDAQ Investopedia
Jan-17-20 08:16AM	Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status Zacks
Jan-16-20 09:00AM	FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients PR Newswire
Jan-13-20 04:01PM	Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary PR Newswire
Jan-08-20 09:27AM	2019 Review: Top Hedge Fund Stocks vs. Arena Pharmaceuticals, Inc. (ARNA) Insider Monkey

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aurentz Vincent	Executive VP and CBO	Feb 16	Option Exercise	14.80	2,524	37,354	29,524	Feb 18 09:00 PM
Aurentz Vincent	Executive VP and CBO	Feb 16	Sale	85.00	2,524	214,540	27,000	Feb 18 09:00 PM
Lisicki Robert	EVP, Chief Commercial Officer	Feb 02	Option Exercise	40.95	17,500	716,625	26,941	Feb 04 08:57 PM
Lisicki Robert	EVP, Chief Commercial Officer	Feb 02	Sale	78.87	17,500	1,380,308	9,441	Feb 04 08:57 PM
Munshi Amit	President and CEO	Jan 19	Option Exercise	15.50	50,000	775,000	57,750	Jan 20 09:05 PM
Dallas Jayson Donald Alexander	Director	Jan 19	Sale	80.50	1,327	106,824	5,308	Jan 20 09:06 PM
Munshi Amit	President and CEO	Jan 19	Sale	80.14	50,000	4,006,760	7,750	Jan 20 09:05 PM
Munshi Amit	President and CEO	Jan 15	Option Exercise	15.50	50,000	775,000	57,750	Jan 20 09:05 PM
Munshi Amit	President and CEO	Jan 15	Sale	80.24	50,000	4,011,976	7,750	Jan 20 09:05 PM
Munshi Amit	President and CEO	Jan 12	Sale	75.12	14,877	1,117,569	7,750	Jan 14 08:43 PM
Lisicki Robert	EVP, Chief Commercial Officer	Jan 07	Option Exercise	0.00	12,600	0	12,600	Jan 11 09:19 PM
Aurentz Vincent	Executive VP and CBO	Jan 07	Option Exercise	0.00	18,000	0	27,000	Jan 11 09:18 PM
Munshi Amit	President and CEO	Jan 07	Option Exercise	0.00	23,400	0	31,150	Jan 11 09:17 PM
Dallas Jayson Donald Alexander	Director	Dec 11	Buy	69.31	5	347	6,635	Dec 15 04:07 PM
Dallas Jayson Donald Alexander	Director	Dec 08	Buy	66.25	5	331	6,630	Dec 09 04:03 PM
Munshi Amit	President and CEO	Dec 08	Sale	70.00	6,517	456,198	7,750	Dec 09 04:02 PM
Lisicki Robert	EVP, Chief Commercial Officer	Dec 01	Sale	66.06	3,872	255,786	0	Dec 03 04:02 PM
Lisicki Robert	EVP, Chief Commercial Officer	Nov 25	Option Exercise	0.00	6,300	0	6,300	Nov 30 04:02 PM
Cabell Christopher	EVP, Head of R&D, and CMO	Nov 25	Option Exercise	0.00	2,500	0	2,500	Nov 30 04:01 PM
Munshi Amit	President and CEO	Nov 25	Option Exercise	0.00	11,700	0	19,450	Nov 30 04:00 PM
Aurentz Vincent	Executive VP and CBO	Nov 25	Option Exercise	0.00	9,000	0	9,000	Nov 30 04:00 PM
Munshi Amit	President and CEO	Aug 31	Option Exercise	15.50	50,000	775,000	57,750	Aug 31 08:41 PM
Munshi Amit	President and CEO	Aug 31	Sale	70.10	50,000	3,505,035	7,750	Aug 31 08:41 PM
Munshi Amit	President and CEO	Aug 28	Option Exercise	15.50	50,000	775,000	57,750	Aug 31 08:41 PM
Munshi Amit	President and CEO	Aug 28	Sale	70.00	50,000	3,500,000	7,750	Aug 31 08:41 PM
Nova Tina Susan	Director	Aug 26	Option Exercise	18.13	17,300	313,600	33,876	Aug 28 05:21 PM
Nova Tina Susan	Director	Aug 26	Sale	67.94	17,300	1,175,303	16,576	Aug 28 05:21 PM
Lisicki Robert	EVP, Chief Commercial Officer	Aug 04	Option Exercise	40.95	30,000	1,228,500	30,000	Aug 06 04:38 PM
Lisicki Robert	EVP, Chief Commercial Officer	Aug 04	Sale	63.34	30,000	1,900,345	0	Aug 06 04:38 PM
Cabell Christopher	EVP, Head of R&D, and CMO	Jul 15	Option Exercise	26.28	13,000	341,640	13,000	Jul 17 05:23 PM
Cabell Christopher	EVP, Head of R&D, and CMO	Jul 15	Sale	68.00	13,000	884,000	0	Jul 17 05:23 PM
Soni Manmeet Singh	Director	Jun 17	Sale	62.74	304	19,073	5,902	Jun 18 05:07 PM
Soni Manmeet Singh	Director	Jun 15	Sale	60.12	1,327	79,779	6,206	Jun 16 08:54 PM
Munshi Amit	President and CEO	Jun 03	Option Exercise	15.35	50,000	767,675	57,750	Jun 04 06:34 PM
Munshi Amit	President and CEO	Jun 03	Sale	68.54	50,000	3,427,236	7,750	Jun 04 06:34 PM
Munshi Amit	President and CEO	Jun 02	Option Exercise	14.60	50,000	730,000	57,750	Jun 04 06:34 PM
Aurentz Vincent	Executive VP and CBO	Jun 02	Option Exercise	19.80	25,000	495,000	25,000	Jun 04 06:40 PM
Aurentz Vincent	Executive VP and CBO	Jun 02	Sale	65.00	25,000	1,625,023	0	Jun 04 06:40 PM
Munshi Amit	President and CEO	Jun 02	Sale	65.00	50,000	3,250,000	7,750	Jun 04 06:34 PM
Munshi Amit	President and CEO	May 22	Option Exercise	14.60	34,800	508,080	42,550	May 22 07:31 PM
Munshi Amit	President and CEO	May 22	Sale	58.12	34,800	2,022,608	7,750	May 22 07:31 PM
Munshi Amit	President and CEO	May 21	Option Exercise	14.60	50,000	730,000	57,750	May 22 07:31 PM
Munshi Amit	President and CEO	May 21	Sale	55.00	50,000	2,750,000	7,750	May 22 07:31 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience